j2 Global, Inc. (JCOM) formed multiple bottom with $71.85 target or 7.00% below today’s $77.26 share price. j2 Global, Inc. (JCOM) has $3.74B valuation. The stock decreased 0.36% or $0.28 during the last trading session, reaching $77.26. About 13,318 shares traded. j2 Global, Inc. (NASDAQ:JCOM) has risen 30.53% since January 12, 2017 and is uptrending. It has outperformed by 13.83% the S&P500.
Versartis, Inc. operates as an endocrine-focused biopharmaceutical firm in the United States. The company has market cap of $73.41 million. The firm is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase III clinical trials for the treatment of growth hormone deficiency. It currently has negative earnings. It develops drug candidates that it has licensed from Amunix Operating, Inc.
Analysts await Versartis, Inc. (NASDAQ:VSAR) to report earnings on February, 20. They expect $-0.98 EPS, down 53.13% or $0.34 from last year’s $-0.64 per share. After $-1.40 actual EPS reported by Versartis, Inc. for the previous quarter, Wall Street now forecasts -30.00% EPS growth.
Since January 1, 0001, it had 0 insider purchases, and 5 selling transactions for $7.02 million activity.
The stock decreased 1.20% or $0.03 during the last trading session, reaching $2.05. About 20,208 shares traded. Versartis, Inc. (VSAR) has risen 103.18% since January 12, 2017 and is uptrending. It has outperformed by 86.48% the S&P500.
Ratings analysis reveals 100% of Versartis’s analysts are positive. Out of 3 Wall Street analysts rating Versartis, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. VSAR was included in 3 notes of analysts from October 4, 2016. SunTrust initiated Versartis, Inc. (NASDAQ:VSAR) rating on Friday, December 2. SunTrust has “Buy” rating and $25.0 target. The rating was upgraded by Credit Suisse to “Outperform” on Tuesday, December 20. The rating was initiated by Piper Jaffray with “Overweight” on Tuesday, October 4.
Alpinvest Partners B.V. holds 0.34% of its portfolio in Versartis, Inc. for 33,076 shares. Emory University owns 96,222 shares or 0.19% of their US portfolio. Moreover, Perceptive Advisors Llc has 0.18% invested in the company for 1.89 million shares. The New York-based Ghost Tree Capital Llc has invested 0.14% in the stock. Sabby Management Llc, a New Jersey-based fund reported 707,300 shares.
Analysts await j2 Global, Inc. (NASDAQ:JCOM) to report earnings on February, 8. They expect $1.69 earnings per share, up 14.97% or $0.22 from last year’s $1.47 per share. JCOM’s profit will be $81.81 million for 11.43 P/E if the $1.69 EPS becomes a reality. After $1.27 actual earnings per share reported by j2 Global, Inc. for the previous quarter, Wall Street now forecasts 33.07% EPS growth.